GHRP-2: Clinical Guide for Prescribing Practices
GHRP-2 (Pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that stimulates GH release through the ghrelin receptor. It is one of the original GHRPs with strong clinical research history, producing potent GH release with moderate appetite stimulation. It is commonly combined with GHRH analogs for synergistic GH optimization.
Also Known As
How GHRP-2 Works
GHRP-2 (Pralmorelin) is a synthetic hexapeptide (D-Ala-D-bNal-Ala-Trp-D-Phe-Lys-NH2) that activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering intracellular calcium mobilization and GH vesicle exocytosis [1]. It also acts at the hypothalamic level to suppress somatostatin tone and stimulate GHRH neurons, creating a dual mechanism for GH amplification [2]. GHRP-2 produces stronger GH release than ipamorelin but with moderate cross-reactivity at ACTH and cortisol pathways [3].
Clinical Evidence
GHRP-2 has been used as a diagnostic agent for GH deficiency in Japan (approved as Pralmorelin) [4]. Clinical studies demonstrate strong, dose-dependent GH release with peak levels occurring 15 to 30 minutes post-injection [1]. Comparative trials show GHRP-2 produces approximately 50% more GH release than ipamorelin at equivalent doses, but with measurable cortisol and prolactin co-stimulation [3]. Synergistic effects with GHRH analogs produce 5 to 10 fold increases in GH output compared to either agent alone [2].
Clinical Uses
Patient Selection and Screening
Appropriate for patients requiring stronger GH stimulation than ipamorelin provides, particularly those with more significant GH decline or who have shown suboptimal response to selective secretagogues [2]. Also suitable when moderate appetite stimulation is therapeutically desirable (underweight, post-surgical recovery). Avoid in patients with anxiety disorders (cortisol elevation concern) [3], hyperprolactinemia, or uncontrolled metabolic disease. Screen with IGF-1, cortisol, prolactin, and comprehensive metabolic panel at baseline [4].
Dosing and Administration
Standard dosing is 100 to 300mcg subcutaneously, 2 to 3 times daily on an empty stomach (minimum 30 minutes before meals or at bedtime) [1][2]. Start at 100mcg twice daily and titrate based on response and tolerability. Most effective when combined with a GHRH analog (CJC-1295 100 to 200mcg or sermorelin 200 to 300mcg) at the same injection time for synergistic effect. Cycling is recommended for long-term protocols (8 to 12 weeks on, 2 to 4 weeks off) to minimize receptor desensitization, though less critical than with hexarelin. Monitor cortisol and prolactin at 4 to 6 weeks [3]. All dosing decisions require physician clinical judgment.
Route: Subcutaneous injection
Protocol notes: Administered via subcutaneous injection, typically 100-300mcg 2-3 times daily. Most effective when combined with a GHRH analog (CJC-1295 or sermorelin). Best administered on an empty stomach, 30 minutes before meals or before bedtime.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
GHRP-2 occupies a mid-tier position in GH peptide programs, priced between selective ipamorelin protocols and premium tesamorelin offerings. Wholesale costs typically range from $30 to $60 per vial. Patient pricing for GHRP-2 protocols (often combined with a GHRH analog) ranges from $200 to $400 per month. It serves as a useful step-up option for patients who have plateaued on ipamorelin-based protocols [4], allowing practices to offer tiered GH optimization programs with escalating intensity and pricing.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe GHRP-2 through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
How does GHRP-2 compare to ipamorelin?
Why should GHRP-2 be combined with a GHRH analog?
References
- Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545
- Arvat E et al. Preliminary evidence for GHRP-2 activity in humans. J Endocrinol Invest. 1994;17(7):539-544
- Laferrere B et al. Growth hormone releasing peptide-2 (GHRP-2) and cortisol, ACTH, and prolactin in humans. J Clin Endocrinol Metab. 2005;90(3):1418-1422
- Hataya Y et al. GHRP-2 (Pralmorelin) as a diagnostic agent for GH deficiency in adults. Endocr J. 2007;54(1):41-44
Related Peptides in Growth Hormone Support
CJC-1295/Ipamorelin
Growth Hormone Support
View Guide →
AOD-9604
Growth Hormone Support
View Guide →
Tesamorelin
Growth Hormone Support
View Guide →
Sermorelin
Growth Hormone Support
View Guide →
Ipamorelin
Growth Hormone Support
View Guide →
MK-677
Growth Hormone Support
View Guide →
GHRP-6
Growth Hormone Support
View Guide →
Hexarelin
Growth Hormone Support
View Guide →
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe GHRP-2 Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe GHRP-2 Through Karpa